重药控股(000950) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was CNY 14,477,230,753.69, representing an increase of 88.89% compared to CNY 7,664,345,566.49 in the same period last year[10] - Net profit attributable to shareholders decreased by 5.52% to CNY 79,524,791.42 from CNY 84,168,661.88 year-on-year[10] - The net profit after deducting non-recurring gains and losses fell by 26.50% to CNY 57,265,656.81 compared to CNY 77,913,035.78 in the previous year[10] - The company reported a net profit of ¥4,739,288,439.02, up from ¥4,659,763,647.60, reflecting an increase of 1.7%[71] - Net profit for the current period was ¥133,286,652.92, up from ¥95,041,380.02 in the previous period, indicating a growth of approximately 40.2%[84] - The total comprehensive income for the current period was ¥133,286,652.92, compared to ¥94,766,380.52 in the previous period, marking an increase of approximately 40.6%[88] - The company reported a significant increase in sales expenses, which totaled ¥439,701,802.50, compared to ¥247,153,986.48 in the previous period, reflecting an increase of about 77.8%[81] Assets and Liabilities - The company's total assets increased by 6.78% to CNY 45,309,808,002.72 from CNY 42,432,466,239.45 at the end of the previous year[10] - Total assets increased to ¥45,309,808,002.72 from ¥42,432,466,239.45, representing a rise of 6.6%[65] - Current liabilities totaled ¥28,445,799,262.98, compared to ¥27,161,961,214.55, an increase of 4.7%[68] - Total liabilities reached ¥34,667,427,739.07, up from ¥31,951,885,635.48, indicating an increase of 8.5%[68] - The company’s total non-current liabilities rose to ¥6,221,628,476.09 from ¥4,789,924,420.93, an increase of 30.0%[68] - Total liabilities rose from 31,951,885,635.48 CNY to 32,340,693,097.51 CNY, an increase of about 1.2%[111] Cash Flow - The net cash flow from operating activities was negative at CNY -2,547,529,457.48, compared to CNY -2,027,461,419.24 in the previous year[10] - The cash flow from operating activities shows a net outflow of -2,547,529,457.48, compared to -2,027,461,419.24 in the previous period[100] - The cash inflow from financing activities is 7,352,747,582.06, up from 5,001,987,853.65 in the previous period[102] - The cash and cash equivalents at the end of the period amount to 1,776,514,625.42, down from 1,936,074,300.10 in the previous period[102] - The cash outflow from investment activities was primarily due to payments for fixed assets and other long-term assets totaling 59,376,245.45 CNY[106] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 36,619[15] - The largest shareholder, Chongqing Pharmaceutical Health Industry Co., Ltd., held 38.47% of the shares, totaling 664,900,806 shares[15] Investments and Expenses - The company received government subsidies amounting to CNY 5,879,203.01, primarily from government grants[10] - The company’s management expenses grew by 48.64% to ¥253,768,109.58, largely due to the integration of newly acquired companies[28] - Research and development expenses for the current period were ¥3,265,576.96, significantly higher than ¥34,530.54 in the previous period, indicating a substantial increase in investment in innovation[81] - The company achieved an investment income of ¥82,519,449.39, compared to ¥67,550,221.92 in the previous period, reflecting an increase of approximately 22.1%[81] Other Financial Metrics - The weighted average return on net assets was 0.89%, down from 1.01% in the same period last year, a decrease of 0.12%[10] - The ending balance of cash and cash equivalents was CNY 3,595,858,715.67, a decrease from CNY 4,604,968,083.76 at the end of the previous period[62] - The company reported no derivative investments during the reporting period[43] - The company has no significant contracts affecting daily operations during the reporting period[44] - The first quarter report was not audited[118]